Xencor (XNCR) Reports In-Line Q3 EPS

Xencor (NASDAQ: XNCR) reported Q3 EPS of ($0.20), in-line with the analyst estimate of ($0.20). Revenue for the quarter came in at $7.8 million versus the consensus estimate of $9.71 million.

Cash, cash equivalents and marketable securities totaled $301.9 million as of September 30, 2016, compared to $193.3 million on December 31, 2015.

"During the third quarter, we initiated clinical trials across our internal pipeline of XmAb programs, including Phase 1 studies of subcutaneously administered XmAb®5871 and XmAb®7195, and a first-in-human Phase 1 study of our lead immuno-oncology bispecific antibody candidate, XmAb®14045," said Bassil Dahiyat, Ph.D., president and chief executive officer of Xencor. "With these milestones complete and a strong cash position, we expect to report data from multiple clinical trials in the year ahead, while also initiating studies of additional bispecific oncology candidates and continuing to explore the breadth of our Fc engineering technology."

For earnings history and earnings-related data on Xencor (XNCR) click here.

You May Also Be Interested In

• Ford (F) earnings top estimates in Q1 amid strength in Pro unit; stock up
• Plexus Corp (PLXS) Tops Q2 EPS by 7c
• SLM (SLM) Tops Q1 EPS by 20c; offers guidance